High-Throughput Monitoring of Human Papillomavirus Type Distribution

被引:29
作者
Soderlund-Strand, Anna [1 ]
Dillner, Joakim [1 ,2 ,3 ,4 ,5 ]
机构
[1] Skane Univ Hosp, Dept Clin Microbiol, Malmo, Sweden
[2] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[3] Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden
[4] Karolinska Inst, Dept Biostat, Stockholm, Sweden
[5] Karolinska Hosp, S-10401 Stockholm, Sweden
关键词
PREVALENCE; HPV; WOMEN; MEN; INFECTION; VACCINE; DNA; PERSISTENCE; DISEASE; ASSAYS;
D O I
10.1158/1055-9965.EPI-12-1003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is a need for a rapid and cost-effective evaluation of the effects of different human papillomavirus (HPV) vaccination strategies. Sexually active adolescents are a preferred target group for monitoring, as effects on HPV prevalence would be measurable shortly after implementation of vaccination programs. Methods: The Swedish Chlamydia trachomatis testing program offers free Chlamydia trachomatis testing and reaches a majority of all adolescents in the population. We anonymized the 44,146 samples submitted for Chlamydia trachomatis testing in Southern Sweden during March to November 2008 and conducted HPV genotyping using PCR followed by mass spectrometry. Results: The HPV positivity peaked at 54.4% [95% confidence interval (CI), 52.2-56.6] among 21-year-old women and at 15.0% (95% CI, 12.4-17.6) among 23-year-old men. The HPV positivity was 37.8% (95% CI, 37.3-38.3) for women and 11.2% (95% CI, 10.6-11.8) for men. The most prevalent types among women were HPV 16 (10.0%; 95% CI, 9.7-10.3) and HPV 51 (6.0%; 95% CI, 5.7-6.3) and, among men, HPV 16 (2.1%; 95% CI, 1.8-2.4) and HPV 6 and HPV 51 (1.7%; 95% CI, 1.5-1.9). Conclusion: The high HPV prevalences seen in the Chlamydia trachomatis screening population enables monitoring of the HPV type distribution among sexually active adolescents at high precision. Impact: Effectiveness of HPV vaccination programs in terms of reducing HPV infections has been difficult to measure because of logistic constraints. We describe a system for high-throughput monitoring of HPV type-specific prevalences using samples from the Chlamydia trachomatis screening program. Cancer Epidemiol Biomarkers Prev; 22(2); 242-50. (c) 2012 AACR.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 23 条
[1]   Human papillomavirus infection in men attending a sexually transmitted disease clinic [J].
Baldwin, SB ;
Wallace, DR ;
Papenfuss, MR ;
Abrahamsen, M ;
Vaught, LC ;
Kornegay, JR ;
Hallum, JA ;
Redmond, SA ;
Giuliano, AR .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (07) :1064-1070
[2]   The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].
Brown, Darron R. ;
Kjaer, Susanne K. ;
Sigurdsson, Kristjan ;
Iversen, Ole-Erik ;
Hernandez-Avila, Mauricio ;
Wheeler, Cosette M. ;
Perez, Gonzalo ;
Koutsky, Laura A. ;
Tay, Eng Hseon ;
Garcia, Patricia ;
Ault, Kevin A. ;
Garland, Suzanne M. ;
Leodolter, Sepp ;
Olsson, Sven-Eric ;
Tang, Grace W. K. ;
Ferris, Daron G. ;
Paavonen, Jorma ;
Steben, Marc ;
Bosch, F. Xavier ;
Dillner, Joakim ;
Joura, Elmar A. ;
Kurman, Robert J. ;
Majewski, Slawomir ;
Munoz, Nubia ;
Myers, Evan R. ;
Villa, Luisa L. ;
Taddeo, Frank J. ;
Roberts, Christine ;
Tadesse, Amha ;
Bryan, Janine ;
Lupinacci, Lisa C. ;
Giacoletti, Katherine E. D. ;
Sings, Heather L. ;
James, Margaret ;
Hesley, Teresa M. ;
Barra, Eliav .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935
[3]   Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings [J].
Bruni, Laia ;
Diaz, Mireia ;
Castellsague, Xavier ;
Ferrer, Elena ;
Bosch, F. Xavier ;
de Sanjose, Silvia .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (12) :1789-1799
[4]   Monitoring of human papillomavirus vaccination [J].
Dillner, J. ;
Arbyn, M. ;
Unger, E. ;
Dillner, L. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 163 (01) :17-25
[5]   Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years [J].
Einstein, Mark H. ;
Baron, Mira ;
Levin, Myron J. ;
Chatterjee, Archana ;
Fox, Bradley ;
Scholar, Sofia ;
Rosen, Jeffrey ;
Chakhtoura, Nahida ;
Lebacq, Marie ;
van der Most, Robbert ;
Moris, Philippe ;
Giannini, Sandra L. ;
Schuind, Anne ;
Datta, Sanjoy K. ;
Descamps, Dominique .
HUMAN VACCINES, 2011, 7 (12) :1359-1373
[6]   Global Proficiency Study of Human Papillomavirus Genotyping [J].
Eklund, Carina ;
Zhou, Tiequn ;
Dillner, Joakim .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (11) :4147-4155
[7]   WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland [J].
Ferguson, Morag ;
Wilkinson, Dianna E. ;
Zhou, TieQun .
VACCINE, 2009, 27 (03) :337-347
[8]   Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men [J].
Fife, KH ;
Coplan, PM ;
Jansen, KU ;
DiCello, AC ;
Brown, DR ;
Rojas, C ;
Su, L .
SEXUALLY TRANSMITTED DISEASES, 2003, 30 (03) :246-248
[9]   Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program [J].
Garland, Suzanne M. ;
Brotherton, Julia M. L. ;
Condon, John R. ;
McIntyre, Peter B. ;
Stevens, Matthew P. ;
Smith, David W. ;
Tabrizi, Sepehr N. .
BMC MEDICINE, 2011, 9
[10]   The human papillomavirus infection in men study: Human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States [J].
Giuliano, Anna R. ;
Lazcano-Ponce, Eduardo ;
Villa, Luisa L. ;
Flores, Roberto ;
Salmeron, Jorge ;
Lee, Ji-Hyun ;
Papenfuss, Mary R. ;
Abrahamsen, Martha ;
Jolles, Emily ;
Nielson, Carrie M. ;
Baggio, Maria Luisa ;
Silva, Roberto ;
Quiterio, Manuel .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (08) :2036-2043